Neurological Surgery 脳神経外科50巻1号

2022年01月発行

特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅱ良性脳腫瘍

髄膜腫—Precision medicineの可能性

著者： 山口秀¹ 藤村幹¹

所属機関： ¹北海道大学大学院医学研究院脳神経外科学教室

ページ範囲：P.132 - P.140

Point
・髄膜腫において本邦で承認されている治療薬は存在しないが，国内外では分子標的治療薬や免疫チェックポイント阻害薬を使用した治験が行われている．
・髄膜腫の包括的遺伝子解析が進み，従来知られていたNF2遺伝子変異以外にも，いくつかの特徴的な遺伝子変異が同定された．
・発見された遺伝子変異は多くがNF2変異と相互排他的に存在し，precision medicineの標的となる可能性がある．

参考文献

1）Parsons DW, et al：An integrated genomic analysis of human glioblastoma multiforme. Science 321：1807-1812, 2008

2）Clark VE, et al：Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339：1077-1080, 2013

3）Nakamura H, et al；Kumamoto Brain Tumor Research Group：Epidemiological study of primary intracranial tumors：a regional survey in Kumamoto prefecture in southern Japan--20-year study. Int J Clin Oncol 16：314-321, 2011

4）Louis DN, et al：The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary. Acta Neuropathol 131：803-820, 2016

5）Sahm F, et al：DNA methylation-based classification and grading system for meningioma：a multicentre, retrospective analysis. Lancet Oncol 18：682-694, 2017

6）Paramasivam N, et al：Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol 138：295-308, 2019

7）Simpson D：The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20：22-39, 1957

8）Bi WL, et al：Meningioma genomics：diagnostic, prognostic, and therapeutic applications. Front Surg 3：40, 2016

9）Yamaguchi S, et al：Prognostic factors for survival in patients with high-grade meningioma and recurrence-risk stratification for application of radiotherapy. PLoS One 9：e97108, 2014

10）Goldbrunner R, et al：EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17：e383-391, 2016

11）Blankenstein MA, et al：Assay of estrogen and progestin receptors in human meningioma cytosols using immunological methods. Clin Chim Acta 165：189-195, 1987

12）Grunberg SM, et al：Long-term administration of mifepristone（RU486）：clinical tolerance during extended treatment of meningioma. Cancer Invest 24：727-733, 2006

13）Lamberts SW, et al：Mifepristone（RU 486）treatment of meningiomas. J Neurol Neurosurg Psychiatry 55：486-490, 1992

14）Ji Y, et al：Double-blind phase Ⅲ randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma：SWOG S9005. J Clin Oncol 33：4093-4098, 2015

15）Arena S, et al：Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66：155-166, 2004

16）Johnson DR, et al：Phase Ⅱ study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 13：530-535, 2011

17）Simó M, et al：Recurrent high-grade meningioma：a phase Ⅱ trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 73：919-923, 2014

18）Barresi V：Angiogenesis in meningiomas. Brain Tumor Pathol 28：99-106, 2011

19）Kaley TJ, et al：Phase Ⅱ trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17：116-121, 2015

20）Furtner J, et al：Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade Ⅱ or Ⅲ meningioma. Neuro Oncol 18：401-407, 2016

21）Lou E, et al：Bevacizumab therapy for adults with recurrent/progressive meningioma：a retrospective series. J Neurooncol 109：63-70, 2012

22）Nayak L, et al：Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109：187-193, 2012

23）Grimm SA, et al：Phase Ⅱ trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. J Clin Oncol 33（Suppl）：2055, 2015

24）Shih KC, et al：A phase Ⅱ trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129：281-288, 2016

25）Seizinger BR, et al：Molecular genetic approach to human meningioma：loss of genes on chromosome 22. Proc Natl Acad Sci USA 84：5419-5423, 1987

26）Yuzawa S, et al：Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Mod Pathol 29：708-716, 2016

27）James MF, et al：NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29：4250-4261, 2009

28）Brastianos PK, et al：Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45：285-289, 2013

29）Graillon T, et al：Combined treatment by octreotide and everolimus：octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol 124：33-43, 2015

30）Graillon T, et al：Everolimus and octreotide for patients with recurrent meningioma：results from the phase Ⅱ CEVOREM trial. Clin Cancer Res 26：552-557, 2020

31）Takahashi K, et al：Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131：861-872, 2007

32）Reuss DE, et al：Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125：351-358, 2013

33）Clark VE, et al：Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48：1253-1259, 2016

34）Abedalthagafi M, et al：Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18：649-655, 2016

35）Hyman DM, et al：AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol 35：2251-2259, 2017

36）Weller M, et al：Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363. J Natl Cancer Inst 109：1-4, 2017

37）Swatek J, et al：Alobar holoprosencephaly with cyclopia-autopsy-based observations from one medical center. Reprod Toxicol 41：80-85, 2013

38）Youngblood MW, et al：Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 133：1345-1354, 2019

39）Okano A, et al：Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep 11：6987, 2021

40）Liu Y, et al：TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520：697-701, 2015

41）Xu J, et al：Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat Nanotechnol 14：388-397, 2019

42）Shankar GM, et al：Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 19：535-545, 2017

43）Shankar GM, Santagata S：BAP1 mutations in high-grade meningioma：implications for patient care. Neuro Oncol 19：1447-1456, 2017

44）Goutagny S, et al：High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 24：184-189, 2014

45）Spiegl-Kreinecker S, et al：TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol 20：1584-1593, 2018

46）Mirian C, et al：Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification：an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 91：378-387, 2020

）in atypical and anaplastic meningiomas. Am J Pathol 159：661-669, 2001

48）Perry A, et al：A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12：183-190, 2002

49）von Achenbach C, et al：Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. Transl Oncol 13：100852, 2020

50）Iwai Y, et al：Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24：26, 2017

51）Du Z, et al：Increased expression of the immune modulatory molecule PD-L1（CD274）in anaplastic meningioma. Oncotarget 6：4704-4716, 2015

52）Karimi S, et al：Programmed death ligand-1（PD-L1）expression in meningioma；prognostic significance and its association with hypoxia and NFKB2 expression. Sci Rep 10：14115, 2020

53）Hao S, et al：Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. J Neurooncol 144：11-20, 2019

54）Karimi S, et al：Clinical significance of checkpoint regulator “Programmed death ligand-1（PD-L1）” expression in meningioma：review of the current status. J Neurooncol 151：443-449, 2021

55）Bi WL, et al：Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma：phase Ⅱ trial results. Neuro Oncol 24：101-113, 2022（Advance Access Date：20 May 2021）

56）Chamberlain MC：Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 84：733-736, 1996

57）Chamberlain MC, et al：Temozolomide for treatment-resistant recurrent meningioma. Neurology 62：1210-1212, 2004

58）Chamberlain MC, et al：Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78：271-276, 2006

59）Newton HB, et al：Hydroxyurea chemotherapy for meningiomas：enlarged cohort with extended follow-up. Br J Neurosurg 18：495-499, 2004